Antibody responses to individual proteins of SARS coronavirus and their neutralization activities
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A novel coronavirus, the severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), was identified as the causative agent of SARS. The profile of specific antibodies to individual proteins of the virus is critical to the development of vaccine and diagnostic tools. In this study, 13 recombinant proteins associated with four structural proteins (S, E, M and N) and five putative uncharacterized proteins (3a, 3b, 6, 7a and 9b) of the SARS-CoV were prepared and used for screening and monitoring their specific IgG antibodies in SARS patient sera by protein microarray. Antibodies to proteins S, 3a, N and 9b were detected in the sera from convalescent-phase SARS patients, whereas those to proteins E, M, 3b, 6 and 7a were undetected. In the detectable specific antibodies, anti-S and anti-N were dominant and could persist in the sera of SARS patients until week 30. Among the rabbit antisera to recombinant proteins S3, N, 3a and 9b, only anti-S3 serum showed significant neutralizing activity to the SARS-CoV infection in Vero E6 cells. The results suggest (1) that anti-S and anti-N antibodies are diagnostic markers and in particular that S3 is immunogenic and therefore is a good candidate as a subunit vaccine antigen; and (2) that, from a virus structure viewpoint, the presence in some human sera of antibodies reacting with two recombinant polypeptides, 3a and 9b, supports the hypothesis that they are synthesized during the virus cycle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
Printing Proteins as Microarrays for High-Throughput Function Determination
MacBeath, G., & Schreiber, S. L. (2000) · Science · doi:10.1126/science.289.5485.1760 · Cited by 2,767
Cited by
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Shi, C.-S., Qi, H.-Y., Boularan, C., Huang, N.-N., Abu-Asab, M., Shelhamer, J. H., & Kehrl, J. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303196 · Cited by 473
Coronavirus vaccine development: from SARS and MERS to COVID-19
Li, Y.-D., Chi, W.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00695-2 · Cited by 453
Accessory proteins of SARS-CoV and other coronaviruses
Liu, D. X., Fung, T. S., Chong, K. K.-L., Shukla, A., & Hilgenfeld, R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.06.013 · Cited by 431
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 425
Serological assays for emerging coronaviruses: Challenges and pitfalls
Meyer, B., Drosten, C., & Müller, M. A. (2014) · Virus Research · doi:10.1016/j.virusres.2014.03.018 · Cited by 410
Eosinophil responses during COVID-19 infections and coronavirus vaccination
Lindsley, A. W., Schwartz, J. T., & Rothenberg, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.021 · Cited by 354
SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses
Jiang, H.-W., Li, Y., Zhang, H.-N., Wang, W., Yang, X., Qi, H., Li, H., Men, D., Zhou, J., & Tao, S.-C. (2020) · Nature Communications · doi:10.1038/s41467-020-17488-8 · Cited by 329
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317
Yan, Y., Chang, L., & Wang, L. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2106 · Cited by 306
Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Coleman, C. M., Liu, Y. V., Mu, H., Taylor, J. K., Massare, M., Flyer, D. C., Glenn, G. M., Smith, G. E., & Frieman, M. B. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.04.016 · Cited by 293
Self-citationDeming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., Whitmore, A., Pickles, R., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 275
Metadata
- Authors
- Qiu, M., Shi, Y., Guo, Z., Chen, Z., He, R., Chen, R., Zhou, D., Dai, E., Wang, X., Si, B., Song, Y., Li, J., Yang, L., Wang, J., Wang, H., Pang, X., Zhai, J., Du, Z., Liu, Y., Zhang, Y., Li, L., Wang, J., Sun, B., & Yang, R.
- Venue
- Microbes and Infection
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 7
- Issue
- 5-6
- Pages
- 882-889
- ISSN
- 1286-4579 (ISSN-L)
- OpenAlex
- W2101168258
- Cited by
- 148
- References
- 2
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.